Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 19/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 0.90 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.65 |
| ▸ | MAOA | P21397 | 3/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyline SCHEMBL29519295 | 0.77 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| Lofexidine SCHEMBL3670274 | 0.74 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL10978713 | 0.74 | NISCH (0.67) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL17887853 | 0.73 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL12313576 | 0.73 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CHTR1AKCNH2 | |
| SCHEMBL17722365 | 0.72 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CNISCHMAOA | |
| Hydrochloric Acid SCHEMBL9654915 | 0.72 | NISCH (0.77) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL3961590 | 0.71 | NISCH (0.75) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL17887785 | 0.71 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL17722363 | 0.71 | ADRA2B (0.76) | ADRA2AADRA2BADRA2CHTR1ANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122305-A1 | Topical Compositions and Methods of Use Thereof | AVON PRODUCTS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122305-A1 | Topical Compositions and Methods of Use Thereof | AVON PRODUCTS, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122305-A1 | Topical Compositions and Methods of Use Thereof | TYR, ADRA2C, ADRA2A | ADRA2A 3/4885ADRA2B 8/4885ADRA2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.